AFMD News and Press, Affimed N.V. From 12/04/23

Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203 Review clinical data for AFM24 in solid tumors Conference call/webcast on Monday, December 11, 2023 at 1:30 p.m. PST / 4:30 p.m. EST / 22:...

2023-11-30 15:42:00 ET More on Affimed Affimed N.V. (AFMD) Q3 2023 Earnings Call Transcript Affimed N.V. 2023 Q3 - Results - Earnings Call Presentation Affimed gains on FDA fast track tag for lymphoma therapy Seeking Alpha’s Quant Rating on Affimed ...

2023-11-14 13:57:07 ET Affimed N.V. (AFMD) Q3 2023 Results Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Alexander Fudukidis - Director and Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Med...

2023-11-14 06:33:03 ET More on Affimed Affimed gains on FDA fast track tag for lymphoma therapy Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial information for Affimed For further details see: Affimed ...

Acimtamig (also known as AFM13) combination with AlloNK ® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024. Acimtamig: Received fast-track designation for the combination of acimtamig and AlloNK ® . LuminICE-203: Received...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Affimed N.V. (AFMD) is expected to report $-0.21 for Q3 2023

2023-11-13 10:21:31 ET More on Affimed Affimed gains on FDA fast track tag for lymphoma therapy Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial information for Affimed For further details see: Affimed ...

MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the International Nonpro...

MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, Novem...